Sterling Capital Management LLC Has $174,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Sterling Capital Management LLC reduced its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 61.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,123 shares of the company's stock after selling 20,607 shares during the quarter. Sterling Capital Management LLC's holdings in Takeda Pharmaceutical were worth $174,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB bought a new position in Takeda Pharmaceutical in the third quarter valued at about $40,000. Farther Finance Advisors LLC increased its position in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Takeda Pharmaceutical in the 4th quarter valued at approximately $52,000. Finally, Cromwell Holdings LLC acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $61,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Down 0.6 %

Shares of Takeda Pharmaceutical stock traded down $0.09 on Friday, hitting $15.03. The stock had a trading volume of 1,544,532 shares, compared to its average volume of 1,863,416. The stock has a 50 day moving average of $14.70 and a 200 day moving average of $13.93. The firm has a market capitalization of $47.81 billion, a P/E ratio of 37.53, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.